文献速递主动脉疾病

胸主动脉腔内修复与开放手术修复后心脏重构及降压药物变化比较

Cardiac remodeling and antihypertensive medication changes after thoracic endovascular aortic repair vs open surgical repair.
PubMed 文献 · J Vasc Surg · 2024-11-16

回顾性分析100例胸主动脉瘤或夹层患者(开放手术50例、腔内修复50例),比较术后降压药物用量及心脏功能变化。多变量模型显示TEVAR患者接受更多降压药物的可能性更高(IRR 1.131,P=0.044),但两组左室射血分数和左室肥厚无显著差异。作者强调需加强术后心脏监测并研发更符合自体主动脉的移植物。

要点

  • TEVAR术后降压药物升级可能性高于开放手术(IRR 1.131,P=0.044)。
  • 术后12、24、36个月两组降压药物数量及剂量无显著差异。
  • 两组左室射血分数和左室肥厚无显著差异。

核心结论

  • TEVAR术后降压药物升级可能性更大,提示术后主动脉僵硬度增加;两组心脏重构无显著差异。
  • 作者强调需改进TEVAR和开放手术患者的术后心脏监测方案,并研发与自体主动脉更兼容的移植物以减少长期心血管并发症。

研究设计与样本

  • 回顾性分析100例胸主动脉瘤或夹层患者,开放手术50例,腔内修复50例。
  • 收集人口学、病史、临床结局及经胸超声心动图结果,以降压药物剂量和数量变化作为血流动力学改变和主动脉僵硬度的替代指标。

主要发现

  • 术后12、24、36个月两组降压药物数量或剂量无统计学显著差异。
  • 多变量广义估计方程模型校正年龄、性别和体表面积后,TEVAR患者接受更多降压药物的可能性更高(IRR 1.131,P=0.044)。
  • 体表面积(IRR 1.266,P=0.001)、高血压(IRR 2.070,P≤0.001)、糖尿病(IRR 1.474,P≤0.001)和终末期肾病(IRR 1.304,P=0.011)也与更多降压药物使用相关。
  • TEVAR和开放手术后β受体阻滞剂(P≤0.001)和利尿剂(P=0.046)使用均显著增加。
  • 两组左室射血分数和左室肥厚无显著差异。

临床怎么用

  • 作者认为TEVAR术后降压药物升级可能性更大,提示术后主动脉僵硬度增加。
  • 作者强调需改进TEVAR和开放手术患者的术后心脏监测方案,并研发与自体主动脉更兼容的移植物以减少长期心血管并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiovascular complications remain one of the major all-cause mortalities among patients who receive either thoracic endovascular aortic repair (TEVAR) or open surgical repair (OSR). Increased aortic stiffness after endograft deployment has been shown to induce left ventricular hypertrophy, diastolic dysfunction, and reduced coronary flow reserve. However, there is limited data on the hemodynamic effects after OSR. The purpose of this study is to compare the cardiovascular and hemodynamic changes after TEVAR and OSR. METHODS: A retrospective analysis of 100 patients with thoracic aortic aneurysm or dissection who underwent open (n = 50) or endovascular repair (n = 50) was conducted. Information on demographics, medical and surgical history, and clinical outcomes were retrieved. Transthoracic echocardiographic imaging results were collected to assess cardiac function. Changes to antihypertensive medication dosage and number were used as surrogate markers for hemodynamic changes and aortic stiffness. RESULTS: No statistically significant differences were observed in antihypertensive medication number or dosage between the TEVAR and OSR group at 12 months, 24 months, and 36 months post-surgery. When adjusting for patient demographic factors of age, sex, and body surface area in a multivariable generalized estimating equation model, patients who underwent TEVAR had a higher likelihood of receiving more antihypertensive medications (incidence rate ratio [IRR], 1.131; P = .044). Patient characteristics such as body surface area (IRR, 1.266; P = .001), hypertension (IRR, 2.070; P ≤ .001), diabetes mellitus (IRR, 1.474; P ≤ .001), and end-stage renal disease (IRR, 1.304; P = .011) were also associated with a higher number of antihypertensive medications. A significant increase in beta-blockers (P ≤ .001) and diuretics (P = .046) intake was observed post-TEVAR and post-OSR. No significant differences in left ventricular ejection fraction and left ventricular hypertrophy were observed between the two groups. CONCLUSIONS: We observed a greater likelihood of antihypertensive medications escalation following TEVAR, suggesting an increase in aortic stiffness postoperatively. No significant differences in cardiac remodeling were observed between the two groups. Our findings emphasize the need for an improved postoperative cardiac surveillance program in patients undergoing both TEVAR and OSR. Furthermore, additional innovation is needed to create aortic grafts that are more compatible with the native aorta to reduce long-term cardiovascular complications.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yuan K, Potluri VK, Gorantla A, et al. Cardiac remodeling and antihypertensive medication changes after thoracic endovascular aortic repair vs open surgical repair. J Vasc Surg. 2024. PMID: 39557314. doi:10.1016/j.jvs.2024.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。